EFFICACY OF CERTOLIZUMAB PEGOL IS NOT AFFECTED BY BASELINE ANTI-INFLIXIMAB ANTIBODY STATUS IN PATIENTS WITH CROHN’S DISEASE WITH SECONDARY INFLIXIMAB FAILURE

(1) Gastroenterology, University Hospital Gasthuisberg, Leuven

(2) Gastroenterology, Imelda General Hospital, Bonheiden, Belgium

(3) Hepatogastroenterology, CHU Lille, Lille, France

(4) Gastroenterology, University of Alberta, Edmonton, Canada

(5) Department of Medicine, University of California, San Diego

(6) Atlanta Gastroenterology Associates, Atlanta, United States

(7) UCB, Braine l’Alleud, Belgium

(8) Gastroenterology, University of Miami, Miami

(9) Gastroenterology & Hepatology, Mayo Clinic, Rochester, United States



This item was part of the IMMFLAMMATORY BOWEL DISEASE I session at Gastro 2009 UEGW/WCOG London (17th UEGW)

This item can be cited as: Gut 2009; 58 (Suppl II) A174